Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-19-019759
Filing Date
2019-04-03
Accepted
2019-04-03 19:32:24
Documents
1
Period of Report
2019-04-03

Document Format Files

Seq Description Document Type Size
1 3 a3.html 3  
1 3 a3.xml 3 4709
  Complete submission text file 0001104659-19-019759.txt   7086
Mailing Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Business Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 908-740-4000
Merck & Co., Inc. (Reporting) CIK: 0000310158 (see all company filings)

State of Incorp.: NJ | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38853 | Film No.: 19730764
SIC: 2834 Pharmaceutical Preparations

Mailing Address ONE MERCK DRIVE WHITEHOUSE STATION NJ 08889
Business Address ONE MERCK DRIVE WHITEHOUSE STATION NJ 08889 908-740-4000
Merck Sharp & Dohme Corp. (Reporting) CIK: 0000942443 (see all company filings)

State of Incorp.: NJ | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38853 | Film No.: 19730765

Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Issuer) CIK: 0001426332 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
SIC: 2834 Pharmaceutical Preparations